Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559013 | 1.00 | TACR1 (0.49) | TACR1CYP3A4CYP2D6SIGMAR1 | |
| SCHEMBL4023028 | 0.89 | TACR1 (0.63) | TACR1CYP3A4CYP2D6 | |
| SCHEMBL4023770 | 0.88 | TACR1 (0.61) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4021339 | 0.85 | PDK1 (0.42) | TACR1 | |
| SCHEMBL4473990 | 0.84 | TACR1 (0.45) | TACR1 | |
| SCHEMBL13949034 | 0.82 | TACR1 (0.63) | TACR1CYP3A4CYP2D6 | |
| SCHEMBL4030300 | 0.82 | TACR1 (0.53) | TACR1 | |
| SCHEMBL4030829 | 0.81 | PDK1 (0.43) | SIGMAR1 | |
| SCHEMBL4703855 | 0.75 | TACR1 (0.63) | TACR1CYP3A4SIGMAR1 | |
| SCHEMBL4030849 | 0.75 | TACR1 (0.47) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625904-B2 | Methods for the treatment of sleep disorders | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080249108-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | US | disclosed |
| US-6951861-B1 | Chemical compounds | SMITHKLINE BEECHAN CORPORATION (US) | 2005-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249108-A1 | Chemical Compounds | CYP11B2, CYP11B1, CYP21A2 | TACR1 159/4885CYP3A4 46/4885CYP2D6 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.